Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPC2001
- Development stage
- Unknown
- Lead developer
- BioPhoenix
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BPC2001 is a recombinant humanized monoclonal antibody developed by BioPhoenix Co., Ltd. that targets the alpha subunit of the interleukin-2 receptor (IL-2Rα), also known as CD25. CD25 is highly expressed on activated T cells, which play a critical role in the development of graft-versus-host disease (GvHD). By binding to CD25, BPC2001 competitively inhibits the binding of IL-2 to its receptor, thereby suppressing T-cell activation and proliferation. The drug is primarily being investigated for the prevention of acute GvHD in patients with hematologic malignancies undergoing haploidentical hematopoietic stem cell transplantation (Haplo-SCT), typically as an adjunct to standard immunosuppressive regimens like the Beijing Protocol.
- Other names
- anti-CD25 monoclonal antibodyanti-CD-25 monoclonal antibodyanti-CD 25 monoclonal antibody
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)
Beyond the preview
Go deeper on BPC2001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPC2001.